{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T03:20:57Z","timestamp":1770175257918,"version":"3.49.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00347-025-02337-0","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:34:42Z","timestamp":1762871682000},"page":"50-63","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Augen\u00e4rztliche Screening-Untersuchungen bei Therapie mit Chloroquin oder Hydroxychloroquin","Ophthalmological screening examinations in treatment with chloroquine or hydroxychloroquine"],"prefix":"10.1007","volume":"123","author":[{"name":"Deutsche Ophthalmologische Gesellschaft e.\u202fV. (DOG)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Kellner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Bertram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Claessens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"J\u00e4gle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Rating","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Spital","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Pfau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Priglinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Berufsverband der Augen\u00e4rzte Deutschlands e.\u202fV. (BVA)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Kellner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Bertram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Claessens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"J\u00e4gle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Rating","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Spital","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Priglinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Retinologische Gesellschaft e.\u202fV. (RG)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Kellner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Bertram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Rating","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Spital","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Pfau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"1","key":"2337_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s42358-020-00134-8","volume":"60","author":"ET dos Reis Neto","year":"2020","unstructured":"dos Reis Neto\u00a0ET, Kakehasi\u00a0AM, de Medeiros Pinheiro\u00a0M, Ferreira\u00a0GA, Marques\u00a0CDL, da Mota\u00a0LMH et\u00a0al (2020) Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. Adv Rheumatol 60(1):32. https:\/\/doi.org\/10.1186\/s42358-020-00134-8","journal-title":"Adv Rheumatol"},{"issue":"4","key":"2337_CR2","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/acr.24850","volume":"75","author":"A Jorge","year":"2023","unstructured":"Jorge\u00a0A, Lu\u00a0N, Choi\u00a0H, Esdaile\u00a0JM, Lacaille\u00a0D, Avina-Zubieta\u00a0JA (2023) Hydroxychloroquine use and cardiovascular events among patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Care Res 75(4):743\u2013748. https:\/\/doi.org\/10.1002\/acr.24850","journal-title":"Arthritis Care Res"},{"issue":"8","key":"2337_CR3","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/acr.24255","volume":"73","author":"A Jorge","year":"2021","unstructured":"Jorge\u00a0A, McCormick\u00a0N, Lu\u00a0N, Zheng\u00a0Y, Esdaile\u00a0J, De Vera\u00a0M et\u00a0al (2021) Hydroxychloroquine and mortality among patients with systemic lupus erythematosus in the general population. Arthritis Care Res 73(8):1219\u20131223. https:\/\/doi.org\/10.1002\/acr.24255","journal-title":"Arthritis Care Res"},{"issue":"7","key":"2337_CR4","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/acr.24550","volume":"74","author":"MR Hoque","year":"2022","unstructured":"Hoque\u00a0MR, Avina-Zubieta\u00a0JA, De Vera\u00a0MA, Qian\u00a0Y, Esdaile\u00a0JM, Xie\u00a0H (2022) Impact of antimalarial adherence on mortality among patients with newly diagnosed systemic lupus erythematosus: a population-based cohort study. Arthritis Care Res 74(7):1089\u20131097. https:\/\/doi.org\/10.1002\/acr.24550","journal-title":"Arthritis Care Res"},{"issue":"8","key":"2337_CR5","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00296-023-05306-5","volume":"43","author":"K Pawlak-Bu\u015b","year":"2023","unstructured":"Pawlak-Bu\u015b\u00a0K, Schmidt\u00a0W, Dudziec\u00a0E, Leszczy\u0144ski\u00a0P (2023) Current treatment of systemic lupus erythematosus: a clinician\u2019s perspective. Rheumatol Int 43(8):1395\u20131407. https:\/\/doi.org\/10.1007\/s00296-023-05306-5","journal-title":"Rheumatol Int"},{"issue":"17","key":"2337_CR6","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1001\/jama.2024.2315","volume":"331","author":"CH Siegel","year":"2024","unstructured":"Siegel\u00a0CH, Sammaritano\u00a0LR (2024) Systemic lupus erythematosus: a\u00a0review. JAMA 331(17):1480\u20131491. https:\/\/doi.org\/10.1001\/jama.2024.2315","journal-title":"JAMA"},{"issue":"11","key":"2337_CR7","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1177\/09612033221115618","volume":"31","author":"O Araujo","year":"2022","unstructured":"Araujo\u00a0O, Hernandez-Rodriguez\u00a0J, Pelegrin\u00a0L, Feliu\u00a0M, Boland\u00a0M, Hernandez-Negrin\u00a0H et\u00a0al (2022) Why lupus patients discontinue antimalarials in real life: a\u00a050\u00a0years-experience from a\u00a0reference centre. Lupus 31(11):1344\u20131354. https:\/\/doi.org\/10.1177\/09612033221115618","journal-title":"Lupus"},{"key":"2337_CR8","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2022.0064","author":"J Mucke","year":"2022","unstructured":"Mucke\u00a0J, Simon\u00a0HU, Burmester\u00a0GR (2022) The safety of antirheumatic drugs. Dtsch \u00c4rztebl Int. https:\/\/doi.org\/10.3238\/arztebl.m2022.0064","journal-title":"Dtsch \u00c4rztebl Int"},{"issue":"4","key":"2337_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/acr2.11531","volume":"5","author":"HY Liu","year":"2023","unstructured":"Liu\u00a0HY, Cramarossa\u00a0G, Pope\u00a0JE (2023) Systemic lupus erythematosus may be a risk factor for antimalarial-induced retinopathy compared with other rheumatologic diseases. ACR Open Rheumatol 5(4):173\u2013179. https:\/\/doi.org\/10.1002\/acr2.11531","journal-title":"ACR Open Rheumatol"},{"issue":"3","key":"2337_CR10","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/IAE.0000000000002408","volume":"39","author":"BH Pham","year":"2019","unstructured":"Pham\u00a0BH, Marmor\u00a0MF (2019) Sequential changes in hydroxychloroquine retinopathy up to 20 years after stopping the drug: implications for mild versus severe toxicity. Retina 39(3):492\u2013501. https:\/\/doi.org\/10.1097\/IAE.0000000000002408","journal-title":"Retina"},{"issue":"6","key":"2337_CR11","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.ophtha.2020.10.029","volume":"128","author":"SJ Ahn","year":"2021","unstructured":"Ahn\u00a0SJ, Seo\u00a0EJ, Kim\u00a0KE, Kim\u00a0YJ, Lee\u00a0BR, Kim\u00a0JG et\u00a0al (2021) Long-term progression of pericentral hydroxychloroquine retinopathy. Ophthalmology 128(6):889\u2013898. https:\/\/doi.org\/10.1016\/j.ophtha.2020.10.029","journal-title":"Ophthalmology"},{"key":"2337_CR12","doi-asserted-by":"publisher","first-page":"1238226","DOI":"10.3389\/fmed.2023.1238226","volume":"10","author":"SJ Ahn","year":"2023","unstructured":"Ahn\u00a0SJ, Kim\u00a0JH (2023) Causes and trends of late diagnosis in Korean patients with hydroxychloroquine retinopathy. Front Med (Lausanne) 10:1238226. https:\/\/doi.org\/10.3389\/fmed.2023.1238226","journal-title":"Front Med (Lausanne)"},{"issue":"6","key":"2337_CR13","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","volume":"123","author":"MF Marmor","year":"2016","unstructured":"Marmor\u00a0MF, Kellner\u00a0U, Lai\u00a0TY, Melles\u00a0RB, Mieler\u00a0WF (2016) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 123(6):1386\u20131394. https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.058","journal-title":"Ophthalmology"},{"issue":"6","key":"2337_CR14","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/art.41683","volume":"73","author":"JT Rosenbaum","year":"2021","unstructured":"Rosenbaum\u00a0JT, Costenbader\u00a0KH, Desmarais\u00a0J, Ginzler\u00a0EM, Fett\u00a0N, Goodman\u00a0SM et\u00a0al (2021) American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 joint statement on hydroxychloroquine use with respect to retinal toxicity. Arthritis Rheumatol 73(6):908\u2013911. https:\/\/doi.org\/10.1002\/art.41683","journal-title":"Arthritis Rheumatol"},{"key":"2337_CR15","doi-asserted-by":"publisher","first-page":"1196815","DOI":"10.3389\/fmed.2023.1196815","volume":"10","author":"IH Yusuf","year":"2023","unstructured":"Yusuf\u00a0IH, Issa\u00a0PC, Ahn\u00a0SJ (2023a) Unmet needs and future perspectives in hydroxychloroquine retinopathy. Front Med (Lausanne) 10:1196815. https:\/\/doi.org\/10.3389\/fmed.2023.1196815","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"2337_CR16","doi-asserted-by":"publisher","first-page":"12330","DOI":"10.1038\/s41598-025-96579-2","volume":"15","author":"K Kato","year":"2025","unstructured":"Kato\u00a0K, Shinoda\u00a0K, Yokogawa\u00a0N, Tajima\u00a0T, Takahashi\u00a0T, Kondo\u00a0M (2025) A real-world descriptive study of screening practices for hydroxychloroquine retinopathy in Japan using an insurance claims database. Sci Rep 15(1):12330. https:\/\/doi.org\/10.1038\/s41598-025-96579-2","journal-title":"Sci Rep"},{"issue":"14","key":"2337_CR17","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1038\/s41433-024-03168-0","volume":"38","author":"IH Yusuf","year":"2024","unstructured":"Yusuf\u00a0IH, Han\u00a0RC, Downes\u00a0SM, Sharma\u00a0SM (2024) The incidence, monitoring coverage and clinical characteristics of hydroxychloroquine retinopathy in the United Kingdom. Eye (Lond) 38(14):2796\u20132804. https:\/\/doi.org\/10.1038\/s41433-024-03168-0","journal-title":"Eye (Lond)"},{"issue":"3","key":"2337_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10198-024-01715-w","volume":"26","author":"SW Quist","year":"2025","unstructured":"Quist\u00a0SW, Dorsthorst\u00a0ST, Freriks\u00a0RD, Postma\u00a0MJ, Hoyng\u00a0CB, van Asten\u00a0F (2025) Cost-effectiveness of hydroxychloroquine retinopathy screening: the current guideline versus no screening and reduced regimens. Eur J Health Econ 26(3):413\u2013425. https:\/\/doi.org\/10.1007\/s10198-024-01715-w","journal-title":"Eur J Health Econ"},{"issue":"1","key":"2337_CR19","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/s41598-023-42816-5","volume":"13","author":"FGP Kalaw","year":"2023","unstructured":"Kalaw\u00a0FGP, Arnett\u00a0J, Baxter\u00a0SL, Walker\u00a0E, Pedersen\u00a0B, Borooah\u00a0S (2023) Trends and practices following the 2016 hydroxychloroquine screening guidelines. Sci Rep 13(1):15618. https:\/\/doi.org\/10.1038\/s41598-023-42816-5","journal-title":"Sci Rep"},{"issue":"10","key":"2337_CR20","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1038\/s41433-022-02291-0","volume":"37","author":"IH Yusuf","year":"2023","unstructured":"Yusuf\u00a0IH, Han\u00a0RC, Downes\u00a0SM, Sharma\u00a0SM (2023b) A nationwide survey of hydroxychloroquine retinopathy presenting to the hospital eye service in the United Kingdom. Eye (Lond) 37(10):2082\u20132088. https:\/\/doi.org\/10.1038\/s41433-022-02291-0","journal-title":"Eye (Lond)"},{"issue":"2","key":"2337_CR21","doi-asserted-by":"publisher","first-page":"166","DOI":"10.7326\/M22-2453","volume":"176","author":"RB Melles","year":"2023","unstructured":"Melles\u00a0RB, Jorge\u00a0AM, Marmor\u00a0MF, Zhou\u00a0B, Conell\u00a0C, Niu\u00a0J et\u00a0al (2023) Hydroxychloroquine dose and risk for incident retinopathy: a cohort study. Ann Intern Med 176(2):166\u2013173. https:\/\/doi.org\/10.7326\/M22-2453","journal-title":"Ann Intern Med"},{"issue":"12","key":"2337_CR22","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","volume":"132","author":"RB Melles","year":"2014","unstructured":"Melles\u00a0RB, Marmor\u00a0MF (2014) The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 132(12):1453\u20131460. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.3459","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"2337_CR23","doi-asserted-by":"publisher","first-page":"e2410677","DOI":"10.1001\/jamanetworkopen.2024.10677","volume":"7","author":"AM Jorge","year":"2024","unstructured":"Jorge\u00a0AM, Melles\u00a0RB, Marmor\u00a0MF, Zhou\u00a0B, Zhang\u00a0Y, Choi\u00a0HK (2024) Risk factors for hydroxychloroquine retinopathy and its subtypes. JAMA Netw Open 7(5):e2410677. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.10677","journal-title":"JAMA Netw Open"},{"issue":"10","key":"2337_CR24","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1038\/s41433-024-03044-x","volume":"38","author":"HI Chiu","year":"2024","unstructured":"Chiu\u00a0HI, Cheng\u00a0HC, Wu\u00a0CC, Chen\u00a0SJ, Hwang\u00a0DK, Huang\u00a0YM et\u00a0al (2024) Exome sequencing and genome-wide association analyses unveils the genetic predisposition in hydroxychloroquine retinopathy. Eye (Lond) 38(10):1926\u20131932. https:\/\/doi.org\/10.1038\/s41433-024-03044-x","journal-title":"Eye (Lond)"},{"issue":"1","key":"2337_CR25","doi-asserted-by":"publisher","first-page":"7674","DOI":"10.1038\/s41598-024-58391-2","volume":"14","author":"PC Liu","year":"2024","unstructured":"Liu\u00a0PC, Luo\u00a0SL, Lv\u00a0MN, Wang\u00a0Y, Li\u00a0JB, Yu\u00a0SJ et\u00a0al (2024) Effect of hydroxychloroquine blood concentration on the efficacy and ocular toxicity of systemic lupus erythematosus. Sci Rep 14(1):7674. https:\/\/doi.org\/10.1038\/s41598-024-58391-2","journal-title":"Sci Rep"},{"issue":"14","key":"2337_CR26","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1001\/jama.2022.13591","volume":"328","author":"AM Jorge","year":"2022","unstructured":"Jorge\u00a0AM, Mancini\u00a0C, Zhou\u00a0B, Ho\u00a0G, Zhang\u00a0Y, Costenbader\u00a0K et\u00a0al (2022) Hydroxychloroquine dose per ophthalmology guidelines and the risk of systemic lupus erythematosus flares. JAMA 328(14):1458\u20131460. https:\/\/doi.org\/10.1001\/jama.2022.13591","journal-title":"JAMA"},{"key":"2337_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000841","author":"S Fasano","year":"2023","unstructured":"Fasano\u00a0S, Messiniti\u00a0V, Iudici\u00a0M, Coscia\u00a0MA, Ciccia\u00a0F (2023) Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus. Lupus Sci Med. https:\/\/doi.org\/10.1136\/lupus-2022-000841","journal-title":"Lupus Sci Med"},{"key":"2337_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2024-001434","author":"MJI Dias","year":"2025","unstructured":"Dias\u00a0MJI, Chevalier\u00a0K, Vasseur\u00a0V, Laumonier\u00a0E, Derrien\u00a0S, Morel\u00a0N et\u00a0al (2025) Comparison of flares in 85 patients with SLE who maintained, discontinued or reduced dose of hydroxychloroquine during a prospective study of ophthalmological screening for retinopathy (PERFOCTAPS Study). Lupus Sci Med. https:\/\/doi.org\/10.1136\/lupus-2024-001434","journal-title":"Lupus Sci Med"},{"issue":"1","key":"2337_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ophtha.2014.07.018","volume":"122","author":"RB Melles","year":"2015","unstructured":"Melles\u00a0RB, Marmor\u00a0MF (2015) Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology 122(1):110\u2013116. https:\/\/doi.org\/10.1016\/j.ophtha.2014.07.018","journal-title":"Ophthalmology"},{"issue":"2","key":"2337_CR30","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ophtha.2014.07.056","volume":"122","author":"C Cukras","year":"2015","unstructured":"Cukras\u00a0C, Huynh\u00a0N, Vitale\u00a0S, Wong\u00a0WT, Ferris\u00a0FL 3rd, Sieving\u00a0PA (2015) Subjective and objective screening tests for hydroxychloroquine toxicity. Ophthalmology 122(2):356\u2013366. https:\/\/doi.org\/10.1016\/j.ophtha.2014.07.056","journal-title":"Ophthalmology"},{"issue":"6","key":"2337_CR31","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.ophtha.2015.02.011","volume":"122","author":"AC Tsang","year":"2015","unstructured":"Tsang\u00a0AC, Ahmadi Pirshahid\u00a0S, Virgili\u00a0G, Gottlieb\u00a0CC, Hamilton\u00a0J, Coupland\u00a0SG (2015) Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test. Ophthalmology 122(6):1239\u20131251.e4. https:\/\/doi.org\/10.1016\/j.ophtha.2015.02.011","journal-title":"Ophthalmology"},{"issue":"1","key":"2337_CR32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ophtha.2020.06.021","volume":"128","author":"KE Kim","year":"2021","unstructured":"Kim\u00a0KE, Ahn\u00a0SJ, Woo\u00a0SJ, Park\u00a0KH, Lee\u00a0BR, Lee\u00a0YK et\u00a0al (2021) Use of OCT retinal thickness deviation map for hydroxychloroquine retinopathy screening. Ophthalmology 128(1):110\u2013119. https:\/\/doi.org\/10.1016\/j.ophtha.2020.06.021","journal-title":"Ophthalmology"},{"key":"2337_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2023-001608","author":"O Araujo","year":"2024","unstructured":"Araujo\u00a0O, Casaroli-Marano\u00a0RP, Hernandez-Rodriguez\u00a0J, Figueras-Roca\u00a0M, Budi\u00a0V, Morato\u00a0M et\u00a0al (2024) New proposal for a multimodal imaging approach for the subclinical detection of hydroxychloroquine-induced retinal toxicity in patients with systemic lupus erythematosus. BMJ Open Ophthalmol. https:\/\/doi.org\/10.1136\/bmjophth-2023-001608","journal-title":"BMJ Open Ophthalmol"},{"issue":"5","key":"2337_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1167\/tvst.8.5.19","volume":"8","author":"H Alghanem","year":"2019","unstructured":"Alghanem\u00a0H, Padhi\u00a0TR, Chen\u00a0A, Niziol\u00a0LM, Abalem\u00a0MF, Dakki\u00a0N et\u00a0al (2019) Comparison of fundus-guided microperimetry and multifocal electroretinography for evaluating hydroxychloroquine maculopathy. Transl Vis Sci Technol 8(5):19. https:\/\/doi.org\/10.1167\/tvst.8.5.19","journal-title":"Transl Vis Sci Technol"},{"key":"2337_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13101752","author":"KX Cheong","year":"2023","unstructured":"Cheong\u00a0KX, Ong\u00a0CJT, Chandrasekaran\u00a0PR, Zhao\u00a0J, Teo\u00a0KYC, Mathur\u00a0R (2023) Review of retinal imaging modalities for hydroxychloroquine retinopathy. Diagnostics (Basel). https:\/\/doi.org\/10.3390\/diagnostics13101752","journal-title":"Diagnostics (Basel)"},{"issue":"9","key":"2337_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1167\/tvst.9.9.8","volume":"9","author":"R Jauregui","year":"2020","unstructured":"Jauregui\u00a0R, Parmann\u00a0R, Nuzbrokh\u00a0Y, Tsang\u00a0SH, Sparrow\u00a0JR (2020) Spectral-domain optical coherence tomography is more sensitive for hydroxychloroquine-related structural abnormalities than short-wavelength and near-infrared autofluorescence. Transl Vis Sci Technol 9(9):8. https:\/\/doi.org\/10.1167\/tvst.9.9.8","journal-title":"Transl Vis Sci Technol"},{"issue":"12","key":"2337_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1167\/iovs.62.12.28","volume":"62","author":"E Borrelli","year":"2021","unstructured":"Borrelli\u00a0E, Battista\u00a0M, Cascavilla\u00a0ML, Vigano\u00a0C, Borghesan\u00a0F, Nicolini\u00a0N et\u00a0al (2021) Impact of structural changes on multifocal electroretinography in patients with use of hydroxychloroquine. Invest Ophthalmol Vis Sci 62(12):28. https:\/\/doi.org\/10.1167\/iovs.62.12.28","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"2337_CR38","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1136\/bjo.2008.157198","volume":"93","author":"S Kellner","year":"2009","unstructured":"Kellner\u00a0S, Weinitz\u00a0S, Kellner\u00a0U (2009) Spectral domain optical coherence tomography detects early stages of chloroquine retinopathy similar to multifocal electroretinography, fundus autofluorescence and near-infrared autofluorescence. Br J Ophthalmol 93(11):1444\u20131447. https:\/\/doi.org\/10.1136\/bjo.2008.157198","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"2337_CR39","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1136\/bjophthalmol-2018-313350","volume":"103","author":"ST Garrity","year":"2019","unstructured":"Garrity\u00a0ST, Jung\u00a0JY, Zambrowski\u00a0O, Pichi\u00a0F, Su\u00a0D, Arya\u00a0M et\u00a0al (2019) Early hydroxychloroquine retinopathy: optical coherence tomography abnormalities preceding Humphrey visual field defects. Br J Ophthalmol 103(11):1600\u20131604. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-313350","journal-title":"Br J Ophthalmol"},{"issue":"16","key":"2337_CR40","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.3390\/diagnostics14161803","volume":"14","author":"SJ Ahn","year":"2024","unstructured":"Ahn\u00a0SJ (2024) Classification of hydroxychloroquine retinopathy: a literature review and proposal for revision. Diagnostics (Basel) 14(16):1803. https:\/\/doi.org\/10.3390\/diagnostics14161803","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"2337_CR41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/ICB.0000000000001108","volume":"15","author":"MF Marmor","year":"2021","unstructured":"Marmor\u00a0MF, Durbin\u00a0M, de Sisternes\u00a0L, Pham\u00a0BH (2021) Sequential retinal thickness analysis shows hydroxychloroquine damage before other screening techniques. Retin Cases Brief Rep 15(3):185\u2013196. https:\/\/doi.org\/10.1097\/ICB.0000000000001108","journal-title":"Retin Cases Brief Rep"},{"issue":"9","key":"2337_CR42","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.ophtha.2022.05.002","volume":"129","author":"RB Melles","year":"2022","unstructured":"Melles\u00a0RB, Marmor\u00a0MF (2022) Rapid macular thinning is an early indicator of hydroxychloroquine retinal toxicity. Ophthalmology 129(9):1004\u20131013. https:\/\/doi.org\/10.1016\/j.ophtha.2022.05.002","journal-title":"Ophthalmology"},{"key":"2337_CR43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ajo.2022.07.028","volume":"245","author":"KE Kim","year":"2023","unstructured":"Kim\u00a0KE, Kim\u00a0YH, Kim\u00a0J, Ahn\u00a0SJ (2023) Macular ganglion cell complex and peripapillary retinal nerve fiber layer thicknesses in hydroxychloroquine retinopathy. Am J Ophthalmol 245:70\u201380. https:\/\/doi.org\/10.1016\/j.ajo.2022.07.028","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"2337_CR44","doi-asserted-by":"publisher","first-page":"708","DOI":"10.4103\/IJO.IJO_2117_24","volume":"73","author":"S Temkar","year":"2025","unstructured":"Temkar\u00a0S, Mairal\u00a0AT, Sahi\u00a0A, Deb\u00a0AK, Kavadichanda\u00a0CG, Kaliaperumal\u00a0S et\u00a0al (2025) Structural and functional assessment of ganglion cell complex in patients on long-term hydroxychloroquine. Indian J Ophthalmol 73(5):708\u2013712. https:\/\/doi.org\/10.4103\/IJO.IJO_2117_24","journal-title":"Indian J Ophthalmol"},{"key":"2337_CR45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ajo.2019.09.008","volume":"209","author":"SJ Ahn","year":"2020","unstructured":"Ahn\u00a0SJ, Joung\u00a0J, Lee\u00a0BR (2020) Evaluation of hydroxychloroquine retinopathy using ultra-widefield fundus autofluorescence: peripheral findings in the retinopathy. Am J Ophthalmol 209:35\u201344. https:\/\/doi.org\/10.1016\/j.ajo.2019.09.008","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"2337_CR46","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1167\/tvst.9.9.42","volume":"9","author":"C Reichel","year":"2020","unstructured":"Reichel\u00a0C, Berlin\u00a0A, Radun\u00a0V, Tarau\u00a0IS, Hillenkamp\u00a0J, Kleefeldt\u00a0N et\u00a0al (2020) Quantitative fundus autofluorescence in systemic chloroquine\/hydroxychloroquine therapy. Transl Vis Sci Technol 9(9):42. https:\/\/doi.org\/10.1167\/tvst.9.9.42","journal-title":"Transl Vis Sci Technol"},{"issue":"7","key":"2337_CR47","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1167\/tvst.12.7.8","volume":"12","author":"V Radun","year":"2023","unstructured":"Radun\u00a0V, Berlin\u00a0A, Tarau\u00a0IS, Kleefeldt\u00a0N, Reichel\u00a0C, Hillenkamp\u00a0J et\u00a0al (2023) Quantitative fundus autofluorescence in systemic chloroquine\/hydroxychloroquine therapy: one year follow-up. Transl Vis Sci Technol 12(7):8. https:\/\/doi.org\/10.1167\/tvst.12.7.8","journal-title":"Transl Vis Sci Technol"},{"issue":"11","key":"2337_CR48","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00417-018-4117-3","volume":"256","author":"M Bulut","year":"2018","unstructured":"Bulut\u00a0M, Akidan\u00a0M, Gozkaya\u00a0O, Erol\u00a0MK, Cengiz\u00a0A, Cay\u00a0HF (2018) Optical coherence tomography angiography for screening of hydroxychloroquine-induced retinal alterations. Graefes Arch Clin Exp Ophthalmol 256(11):2075\u20132081. https:\/\/doi.org\/10.1007\/s00417-018-4117-3","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"2337_CR49","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1007\/s00417-023-06023-2","volume":"261","author":"A Ferreira","year":"2023","unstructured":"Ferreira\u00a0A, Anjos\u00a0R, Jose-Vieira\u00a0R, Afonso\u00a0M, Abreu\u00a0AC, Monteiro\u00a0S et\u00a0al (2023) Application of optical coherence tomography angiography for microvascular changes in patients treated with hydroxychloroquine: a\u00a0systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol 261(8):2221\u20132233. https:\/\/doi.org\/10.1007\/s00417-023-06023-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"2337_CR50","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s12886-025-04083-y","volume":"25","author":"X Li","year":"2025","unstructured":"Li\u00a0X, Xiong\u00a0C, Luo\u00a0S, Chen\u00a0Y, Li\u00a0M, Wang\u00a0S et\u00a0al (2025) Application of SS-OCTA to evaluate the effects of long-term hydroxychloroquine treatment on retinal structure and microcirculation in patients with systemic lupus erythematosus. BMC Ophthalmol 25(1):288. https:\/\/doi.org\/10.1186\/s12886-025-04083-y","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"2337_CR51","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1167\/iovs.18-26079","volume":"60","author":"Y Solberg","year":"2019","unstructured":"Solberg\u00a0Y, Dysli\u00a0C, Moller\u00a0B, Wolf\u00a0S, Zinkernagel\u00a0MS (2019) Fluorescence lifetimes in patients with hydroxychloroquine retinopathy. Invest Ophthalmol Vis Sci 60(6):2165\u20132172. https:\/\/doi.org\/10.1167\/iovs.18-26079","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"2337_CR52","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1167\/iovs.64.12.29","volume":"64","author":"J Tang","year":"2023","unstructured":"Tang\u00a0J, Liu\u00a0H, Mo\u00a0S, Zhu\u00a0Z, Huang\u00a0H, Liu\u00a0X (2023) Cone density distribution and related factors in patients receiving hydroxychloroquine treatment. Invest Ophthalmol Vis Sci 64(12):29. https:\/\/doi.org\/10.1167\/iovs.64.12.29","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-025-02337-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-025-02337-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-025-02337-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T14:02:56Z","timestamp":1770127376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-025-02337-0"}},"subtitle":["S1-Leitlinie der Deutschen Ophthalmologischen Gesellschaft (DOG), des Berufsverbandes der Augen\u00e4rzte Deutschlands (BVA) und der Retinologischen Gesellschaft (RG)","S1 guidelines of the German Society of Ophthalmology (DOG), the German Professional Association of Ophthalmologists (BVA) and the German Retina Society (RG)"],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":52,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2337"],"URL":"https:\/\/doi.org\/10.1007\/s00347-025-02337-0","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"9 October 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Siehe Tab.\u00a0\n                      \n                      im Anhang","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}